Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Early Phase 1
1(25.0%)
N/A
1(25.0%)
4Total
Phase 1(2)
Early Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03801642Phase 1Completed

Dapagliflozin In Alzheimer's Disease

Role: lead

NCT01128361Not ApplicableCompleted

Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD)

Role: lead

NCT01129115Early Phase 1Completed

Dose Response Study of Aerobic Exercise in Older Adults

Role: lead

NCT00581867Phase 1Completed

Memory and Insulin in Early Alzheimer's Disease

Role: lead

All 4 trials loaded